Fate of lymphocytes after withdrawal of tofacitinib treatment.
Tofacitinib (Tofa) is an inhibitor of Janus Kinase 3, developed for the treatment of autoimmune diseases and for the prevention of transplant rejection. Due to its selective action on proliferating cells, Tofa can offer a way to block T cell activation, without toxic effects on resting cells. Howeve...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2014
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c368fa2460f142dba23c19f4c39d15f0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|